IGC (IGC Pharma, Inc.) סך נכסי החברה

The business model of IGC Pharma, Inc. (IGC) relies on the success of cannabinoid trials against Alzheimer's disease, leaving the company hostage to FDA decisions. Risks are amplified by a critical vulnerability stemming from a lack of diversification within neurology. A retrospective of share value on GURU.Markets shows total assets at 8.71, while operational resilience remains absent until regulatory approval is obtained for the developed drugs.

This indicator determines the financial scale of the business by calculating the total volume of resources via a reverse return on assets (ROA) formula. By analyzing the total asset value, the investor assesses the ability of IGC Pharma, Inc. (IGC) to fund the development of bio-therapies to combat dementia and the risk of impairment of specific pharmaceutical assets should market conditions shift within the neurology segment.